• BioMarin Pharmaceuticals Inc., of Novato, Calif., posted its fourth-quarter and full-year earnings, reporting net revenue from sales of Naglazyme (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI, of $25.5 million for the quarter and $86.2 million for the year. Net revenue from Aldurazyme (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I partnered with Genzyme Corp., of Cambridge, Mass., totaled $35.4 million for the quarter and $123.7 million for the year. Sales of Kuvan (sapropterin dihydrochloride), which gained approval in December for phenylketonuria, brought in revenue of $400,000, related to shipments to specialty pharmacies during its first two weeks on the market. For the quarter, BioMarin posted net income of $2.6 million, which includes the receipt of a $15 million milestone payment from European partner Merck Serono, of Geneva, related to EMEA acceptance of a Kuvan application. The company ended the year with $585.6 million in cash, cash equivalents and short-term investments.

• CV Therapeutics Inc., of Palo Alto, Calif., reported fourth-quarter and full-year earnings, posting a net loss of $34.1 million, or 57 cents per share. Total revenues for the quarter were $22.4 million, of which $20.9 million came from net sales of angina drug Ranexa (ranolazine extended-release tablets). Ranexa sales for the year totaled $66.7 million. The company ended 2007 with a cash position of $179 million. The wider-than-expected loss for the quarter, however, sent shares of CV (NASDAQ:CVTX) down $1.57, or 20.2 percent, to close Wednesday at $6.22.

• Tercica Inc., of Brisbane, Calif., reported fourth-quarter and full-year earnings, posting 2007 sales of $9.6 million for Increlex (mecasermin), approved for treating growth failure in children with severe primary insulin-like growth factor-1 deficiency. The company had a net loss of $18.7 million, or 36 cents per share, for the three months ending Dec. 31, and ended the quarter with a cash position of $113.5 million.